Product name: 11-Deoxymogroside IIIE
Synonym name:
Catalogue No.: BP2040
Cas No.: 1793003-47-0
Formula: C48H82O18
Mol Weight: 947.166
Botanical Source: Siraitiae fructus
Physical Description:
Type of Compound: Triterpenoids
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.
The product could be supplied from milligrams to grams
Inquire for bulk scale.
For Reference Standard and R&D, Not for Human Use Directly.
HPLC of 11-Deoxymogroside IIIE
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
With the global prevalence of metabolic diseases, especially the high incidence of diabetes, developing safe and effective natural anti-diabetic products has become an important direction for drug development. Monk fruit (Siraitia grosvenorii), as a representative of traditional Chinese medicine and natural sweeteners, is notable for its main active ingredient, monk fruit glycoside compounds, known for their low calorie, high sweetness, and multiple bioactive properties. 11-Deoxymogroside IIIE is an important triterpenoid glycoside in monk fruit, and in recent years, it has shown significant pharmacological potential in the field of antidiabetic treatment. This paper systematically reviews the chemical structure, extraction method, pharmacological activity, mechanism of action, and druggability evaluation of 11-deoxymoncarthroside IIIE, aiming to provide scientific evidence for its clinical translation and new drug development.
11-Deoxymondrosin IIIE is a high-molecular-weight triterpene glycoside with a molecular weight of 947.1660, a complex molecular formula, and a steroid framework with multiple glycosyl-linked structures. Its LogP value is 2.5042, indicating moderate hydrophobicity, which facilitates cell membrane penetration but is not prone to excessive accumulation. TPSA (Topological Polar Surface Area) is 298.14, indicating high polarity and the number of hydrogen bond donors/acceptors, which may affect its oral absorption and bioavailability. Low water solubility (0.0952) suggests limited solubility in aqueous media, and appropriate formulation techniques may be needed to improve its bioavailability. The blood-brain barrier has low penetration ability, reducing the risk of central nervous system side effects. The hERG suppression test results were negative, indicating a low risk of cardiotoxicity. The Ames test was 0.0, indicating no significant genotoxicity.
The chemical core of 11-deoxymondroside IIIE is a pentacyclic triterpene backbone, and the characteristic of the 11-hypoxic group sets it apart from other monk glycoside compounds. Its polysaccharide modification imparts strong water solubility and biological activity, and the type and linkage of glycans have a significant impact on their pharmacological effects.
11-Deoxymon Fruit Glycoside IIIE is mainly isolated from monk fruit fruit. Monk fruit is a plant in the gourd family, native to southern China, and its fruit is rich in sweet glycoside components. Traditional extraction processes mostly use water extraction combined with alcohol precipitation. In recent years, the application of ultrasound-assisted extraction, microwave-assisted extraction, and membrane separation technology has significantly improved extraction efficiency and purity.
The typical extraction process generally includes: crushing fresh or dried monk fruit, extracting with hot water or 70% ethanol, filtering and concentrated extract, separating impurities with organic solvents, then purifying by column chromatography (such as silica gel column, reversed-phase C18 column), and finally identifying and separating 11-deoxymonk fruit glycoside IIIE by high-performance liquid chromatography (HPLC). In recent years, the introduction of supercritical CO2 extraction and membrane separation technologies has further optimized extraction processes, ensuring the stability and bioactivity of active ingredients.
11-Deoxymonfruit Glycoside IIIE demonstrated significant antidiabetic activity in multiple in vitro and in vivo experiments. Its main manifestations are improving insulin sensitivity, promoting glucose uptake, inhibiting gluconeogenesis, and regulating lipid metabolism.
Cell model studies have shown that 11-deoxymontang fruit glycoside IIIE can activate the AMPK pathway, enhancing glucose uptake by skeletal muscle cells and adipocytes. It has a significant protective effect on pancreatic islets β cells, reducing oxidative stress and apoptosis induced by high sugar levels. Additionally, 11-deoxymonfruit glycoside IIIE inhibits DPP4 enzyme activity, thereby prolonging the half-life of GLP-1 and promoting insulin secretion.
In a diabetic rat model, oral 11-deoxymontang fruit glycoside IIIE significantly reduced fasting blood glucose and glucose tolerance, improving insulin resistance. It can also regulate lipid metabolism, lower serum triglycerides and cholesterol levels, and alleviate hepatic steatosis. Long-term administration has shown protective effects against diabetic complications such as kidney and retina.
Toxicological studies showed that 11-deoxymon fruit glycoside IIIE showed no significant acute or genotoxicity, and the hERG channel inhibition test was negative, indicating good cardiac safety. The Ames test result was negative, supporting its safety.
The antidiabetic effects of 11-deoxymoncarpin IIIE involve multiple signaling pathways and key molecular targets, mainly including:
AMP-activated protein kinase (AMPK) is a core regulator of cellular energy metabolism. 11-Deoxymoncaside IIIE promotes glucose uptake and fatty acid oxidation by activating AMPK (the PRKAA1 subunit), inhibits gluconeogenesis, and improves metabolic homeostasis.
Sodium-glucose cotransporter 2 (SGLT2) is a key target for renal glucose reabsorption. 11-Deoxymonk Fruit Glycoside IIIE has a certain inhibitory effect on SGLT2, promoting glucose excretion in urine and lowering blood glucose levels.
Glucose kinase (GCK), as a key enzyme in glucose metabolism, can enhance its activity and promote glucose metabolism by 11-deoxymonk fruit glycoside IIIE. Peroxisome proliferator-activated receptor γ (PPARG) regulates lipid metabolism and insulin sensitivity, while 11-deoxymonandaside IIIE improves lipid metabolism abnormalities by modulating PPARG expression.
11-Deoxymondroglycoside IIIE promotes activation of AKT1 and PIK3R1 in the insulin signaling pathway, enhances insulin-mediated glucose transport, and improves insulin resistance.
Dipeptidel peptidase 4 (DPP4) degrades GLP-1 and affects insulin secretion. 11-Deoxymonfruit glycoside IIIE inhibits DPP4 activity, increases GLP-1 levels, and promotes the function of pancreatic islet β cells.
Insulin receptor substrate 1 (IRS1) and glucose transporter 4 (SLC2A4) are key molecules for insulin signaling transduction and glucose uptake. 11-Deoxymon Fruit Glycoside IIIE enhances IRS1 phosphorylation, promotes SLC2A4 transport to cell membranes, and improves glucose uptake efficiency.
In summary, 11-deoxymoncarpin IIIE achieves comprehensive regulation of glucose metabolism through multi-target and multi-pathway synergistic effects.
The druggability evaluation of 11-deoxymoncaside IIIE shows it has good safety and potential efficacy advantages. Its large molecular weight and high polarity may limit its oral bioavailability, but its moderate LogP value and low blood-brain barrier permeability ensure its safety.
Pharmacokinetic studies show that 11-deoxymoncarpin IIIE is absorbed slowly in the body and is mainly converted into active metabolites through intestinal metabolic enzymes and gut microbiota metabolism. Its half-life is moderate, mainly metabolized by the liver, and excreted primarily through bile. Due to low water solubility, formulation design requires technologies such as nanoparticles, liposomes, or inclusions to improve solubility and bioavailability.
Additionally, 11-deoxymontang fruit glycoside IIIE showed no significant hERG channel inhibition or genotoxicity, demonstrating a good safety profile and suitability for subsequent clinical development.
As a natural product derived from the traditional Chinese medicine Luo Han Guo, 11-Deoxy Luo Han Guo Glycoside IIIE shows broad application prospects in the anti-diabetic field. Its multi-target mechanism meets the needs of modern multi-factor diabetes treatment and is especially suitable for combination therapy strategies.
Future research should focus on the following aspects:
In summary, 11-deoxymon fruit glycoside IIIE, as a safe and effective natural antidiabetic candidate compound, has strong potential for clinical translation.
11-Deoxymon Fruit Glycoside IIIE, as an important triterpene sweet glycoside in monk fruit, has become a hot topic in natural product pharmacology research due to its unique chemical structure and multi-target antidiabetic mechanism. Its good safety and multiple pharmacological activities provide new ideas and candidate molecules for diabetes treatment. In the future, through in-depth pharmacological mechanism research, druggability optimization, and clinical validation, it is expected that 11-deoxymoncarside IIIE will advance toward clinical application, benefiting a wide range of diabetes patients.
